These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

507 related items for PubMed ID: 29355896

  • 1. Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysis.
    Stull DE, Griffiths CEM, Gilloteau I, Zhao Y, Guana A, Finlay AY, Sherif B, Houghton K, Puig L.
    Br J Dermatol; 2018 Jun; 178(6):1297-1307. PubMed ID: 29355896
    [Abstract] [Full Text] [Related]

  • 2. Secukinumab significantly reduces psoriasis-related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom.
    Warren RB, Halliday A, Graham CN, Gilloteau I, Miles L, McBride D.
    J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2178-2184. PubMed ID: 29846965
    [Abstract] [Full Text] [Related]

  • 3. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
    Blauvelt A, Reich K, Tsai TF, Tyring S, Vanaclocha F, Kingo K, Ziv M, Pinter A, Vender R, Hugot S, You R, Milutinovic M, Thaçi D.
    J Am Acad Dermatol; 2017 Jan; 76(1):60-69.e9. PubMed ID: 27663079
    [Abstract] [Full Text] [Related]

  • 4. Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study.
    Puig L, Augustin M, Blauvelt A, Gottlieb AB, Vender R, Korman NJ, Thaçi D, Zhao Y, Gilloteau I, Sherif B, Williams N, Guana A, Lebwohl MG.
    J Am Acad Dermatol; 2018 Apr; 78(4):741-748. PubMed ID: 29066271
    [Abstract] [Full Text] [Related]

  • 5. Higher Psoriasis Skin Clearance Is Associated with Lower Annual Indirect Costs in the United States: A Post Hoc Analysis from the CLEAR Study.
    Feldman SR, Zhao Y, Gilloteau I, Graham CN, Miles L, McBride D, Herrera V.
    J Manag Care Spec Pharm; 2018 Jul; 24(7):617-622. PubMed ID: 29952701
    [Abstract] [Full Text] [Related]

  • 6. Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study.
    Blauvelt A, Reich K, Mehlis S, Vanaclocha F, Sofen H, Abramovits W, Zhao Y, Gilloteau I, Davenport E, Williams N, Guana A, Tyring S.
    J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1693-1699. PubMed ID: 28602039
    [Abstract] [Full Text] [Related]

  • 7. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients.
    Abrouk M, Nakamura M, Zhu TH, Farahnik B, Koo J, Bhutani T.
    J Dermatolog Treat; 2017 Sep; 28(6):488-491. PubMed ID: 28042711
    [Abstract] [Full Text] [Related]

  • 8. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
    Thaçi D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, Ziv M, Pinter A, Hugot S, You R, Milutinovic M.
    J Am Acad Dermatol; 2015 Sep; 73(3):400-9. PubMed ID: 26092291
    [Abstract] [Full Text] [Related]

  • 9. Ustekinumab improves health-related quality of life in Korean and Taiwanese patients with moderate to severe psoriasis: results from the PEARL trial.
    Tsai TF, Song M, Shen YK, Schenkel B, Choe YB, Kim NI, Lee JH, Lee JH, Song HJ, Youn JI, PEARL investigators.
    J Drugs Dermatol; 2012 Aug; 11(8):943-9. PubMed ID: 22859239
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
    Augustin M, McBride D, Gilloteau I, O'Neill C, Neidhardt K, Graham CN.
    J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
    [Abstract] [Full Text] [Related]

  • 11. A prospective, interventional assessment of the impact of ustekinumab treatment on psoriasis-related work productivity and activity impairment.
    Beroukhim K, Danesh M, Nguyen C, Farahnik B, Levin E, Leon A, Koo J.
    J Dermatolog Treat; 2016 Nov; 27(6):552-555. PubMed ID: 27052387
    [Abstract] [Full Text] [Related]

  • 12. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial.
    Lebwohl M, Papp K, Han C, Schenkel B, Yeilding N, Wang Y, Krueger GG.
    Br J Dermatol; 2010 Jan; 162(1):137-46. PubMed ID: 19903183
    [Abstract] [Full Text] [Related]

  • 13. Switching from Secukinumab to Ustekinumab in Psoriasis Patients: Results from a Multicenter Experience.
    Chiricozzi A, Conti A, Burlando M, Odorici G, Gaiani F, Panduri S, Malagoli P.
    Dermatology; 2019 Jan; 235(3):213-218. PubMed ID: 30928971
    [Abstract] [Full Text] [Related]

  • 14. Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials.
    Armstrong AW, Lynde CW, McBride SR, Ståhle M, Edson-Heredia E, Zhu B, Amato D, Nikaï E, Yang FE, Gordon KB.
    JAMA Dermatol; 2016 Jun 01; 152(6):661-9. PubMed ID: 26953848
    [Abstract] [Full Text] [Related]

  • 15. Correlation Between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis Treated with Ustekinumab.
    Hesselvig JH, Egeberg A, Loft ND, Zachariae C, Kofoed K, Skov L.
    Acta Derm Venereol; 2018 Mar 13; 98(3):335-339. PubMed ID: 29110019
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept.
    Strober B, Gottlieb AB, Sherif B, Mollon P, Gilloteau I, McLeod L, Fox T, Mordin M, Gnanasakthy A, Papavassilis C, Lebwohl MG.
    J Am Acad Dermatol; 2017 Apr 13; 76(4):655-661. PubMed ID: 28087133
    [Abstract] [Full Text] [Related]

  • 18. Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials.
    Kokolakis G, Warren RB, Strober B, Blauvelt A, Puig L, Morita A, Gooderham M, Körber A, Vanvoorden V, Wang M, de Cuyper D, Madden C, Nunez Gomez N, Lebwohl M.
    Br J Dermatol; 2023 Feb 22; 188(3):330-340. PubMed ID: 36751950
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab.
    Elewski BE, Puig L, Mordin M, Gilloteau I, Sherif B, Fox T, Gnanasakthy A, Papavassilis C, Strober BE.
    J Dermatolog Treat; 2017 Sep 22; 28(6):492-499. PubMed ID: 28266243
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.